Published in J Virol on October 01, 2001
Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins. Microbiol Mol Biol Rev (2001) 2.06
Studies of endogenous retroviruses reveal a continuing evolutionary saga. Nat Rev Microbiol (2012) 1.94
In vitro characterization of a koala retrovirus. J Virol (2006) 1.34
A putative thiamine transport protein is a receptor for feline leukemia virus subgroup A. J Virol (2006) 1.17
Fusion-defective gibbon ape leukemia virus vectors can be rescued by homologous but not heterologous soluble envelope proteins. J Virol (2002) 1.16
Subtle mutational changes in the SU protein of a natural feline leukemia virus subgroup A isolate alter disease spectrum. J Virol (2005) 1.04
Reassessing the role of region A in Pit1-mediated viral entry. J Virol (2002) 1.03
Structure and mechanism of a coreceptor for infection by a pathogenic feline retrovirus. J Virol (2003) 1.03
Feline Pit2 functions as a receptor for subgroup B feline leukemia viruses. J Virol (2001) 0.93
Identification of a retroviral receptor used by an envelope protein derived by peptide library screening. Proc Natl Acad Sci U S A (2007) 0.91
Identification of an extracellular domain within the human PiT2 receptor that is required for amphotropic murine leukemia virus binding. J Virol (2004) 0.91
Identification of residues outside of the receptor binding domain that influence the infectivity and tropism of porcine endogenous retrovirus. J Virol (2008) 0.86
Porcine endogenous retroviruses infect cells lacking cognate receptors by an alternative pathway: implications for retrovirus evolution and xenotransplantation. J Virol (2004) 0.84
Advances in understanding molecular determinants in FeLV pathology. Vet Immunol Immunopathol (2008) 0.83
Genetic and biochemical analyses of receptor and cofactor determinants for T-cell-tropic feline leukemia virus infection. J Virol (2002) 0.83
Distinctive receptor binding properties of the surface glycoprotein of a natural feline leukemia virus isolate with unusual disease spectrum. Retrovirology (2011) 0.82
Feline leukemia virus T entry is dependent on both expression levels and specific interactions between cofactor and receptor. Virology (2006) 0.80
Envelope determinants for dual-receptor specificity in feline leukemia virus subgroup A and T variants. J Virol (2006) 0.80
Identification of two distinct structural regions in a human porcine endogenous retrovirus receptor, HuPAR2, contributing to function for viral entry. Retrovirology (2009) 0.79
The surface glycoprotein of a natural feline leukemia virus subgroup A variant, FeLV-945, as a determinant of disease outcome. Vet Immunol Immunopathol (2011) 0.75
Importance of receptor usage, Fli1 activation, and mouse strain for the stem cell specificity of 10A1 murine leukemia virus leukemogenicity. J Virol (2006) 0.75
Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol (1986) 16.65
Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol (1992) 12.89
Cloning of the cellular receptor for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus. Proc Natl Acad Sci U S A (1994) 4.67
Receptor choice determinants in the envelope glycoproteins of amphotropic, xenotropic, and polytropic murine leukemia viruses. J Virol (1992) 4.58
Characterization of a human gene conferring sensitivity to infection by gibbon ape leukemia virus. Cell Growth Differ (1990) 4.50
Use of retroviral vectors for gene transfer and expression. Methods Enzymol (1993) 3.50
A human amphotropic retrovirus receptor is a second member of the gibbon ape leukemia virus receptor family. Proc Natl Acad Sci U S A (1994) 3.42
HIV entry and tropism: the chemokine receptor connection. AIDS (1997) 3.32
Molecular cloning of a feline leukemia virus that induces fatal immunodeficiency disease in cats. Science (1988) 2.86
Feline leukemia virus subgroup B uses the same cell surface receptor as gibbon ape leukemia virus. J Virol (1992) 2.80
Subgroup classification of feline leukemia and sarcoma viruses by viral interference and neutralization tests. Virology (1973) 2.60
A family of retroviruses that utilize related phosphate transporters for cell entry. J Virol (1994) 2.55
GLVR1, a receptor for gibbon ape leukemia virus, is homologous to a phosphate permease of Neurospora crassa and is expressed at high levels in the brain and thymus. J Virol (1992) 2.37
Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol (1995) 2.36
Nucleotide sequences of a feline leukemia virus subgroup A envelope gene and long terminal repeat and evidence for the recombinational origin of subgroup B viruses. J Virol (1986) 2.34
Functional dissection of the Moloney murine leukemia virus envelope protein gp70. J Virol (1997) 2.24
Nucleotide sequence of the envelope gene of Gardner-Arnstein feline leukemia virus B reveals unique sequence homologies with a murine mink cell focus-forming virus. J Virol (1983) 2.24
Transduction of endogenous envelope genes by feline leukaemia virus in vitro. Nature (1988) 1.94
Properties of a unique form of the murine amphotropic leukemia virus receptor expressed on hamster cells. J Virol (1994) 1.90
Viral genetic determinants of T-cell killing and immunodeficiency disease induction by the feline leukemia virus FeLV-FAIDS. J Virol (1991) 1.83
Enveloped viruses: a common mode of membrane fusion?. Curr Biol (1997) 1.80
Changing virus-host interactions in the course of HIV-1 infection. Immunol Rev (1994) 1.73
Activation of a cell entry pathway common to type C mammalian retroviruses by soluble envelope fragments. J Virol (2000) 1.72
Comparison of cDNAs encoding the gibbon ape leukaemia virus receptor from susceptible and non-susceptible murine cells. J Gen Virol (1994) 1.56
Identification of a cellular cofactor required for infection by feline leukemia virus. Science (2000) 1.49
I-mf, a novel myogenic repressor, interacts with members of the MyoD family. Cell (1996) 1.46
Variable regions A and B in the envelope glycoproteins of feline leukemia virus subgroup B and amphotropic murine leukemia virus interact with discrete receptor domains. J Virol (1997) 1.44
Feline leukemia virus envelope gp70 of subgroups B and C defined by monoclonal antibodies with cytotoxic and neutralizing functions. J Immunol (1983) 1.44
Three distinct envelope domains, variably present in subgroup B feline leukemia virus recombinants, mediate Pit1 and Pit2 receptor recognition. J Virol (1997) 1.41
Substitution of a single amino acid residue is sufficient to allow the human amphotropic murine leukemia virus receptor to also function as a gibbon ape leukemia virus receptor. J Virol (1996) 1.41
Modular organization of the Friend murine leukemia virus envelope protein underlies the mechanism of infection. Proc Natl Acad Sci U S A (2001) 1.37
Suppression of a fusion defect by second site mutations in the ecotropic murine leukemia virus surface protein. J Virol (1999) 1.35
Defective endogenous proviruses are expressed in feline lymphoid cells: evidence for a role in natural resistance to subgroup B feline leukemia viruses. J Virol (1994) 1.34
Mature monocytic cells enter tissues and engraft. Proc Natl Acad Sci U S A (1998) 1.33
Feline leukaemia virus: generation of pathogenic and oncogenic variants. Curr Top Microbiol Immunol (1991) 1.32
Progression to AIDS in macaques is associated with changes in the replication, tropism, and cytopathic properties of the simian immunodeficiency virus variant population. Virology (1995) 1.31
In vivo evolution of a novel, syncytium-inducing and cytopathic feline leukemia virus variant. J Virol (1998) 1.23
An X chromosome gene regulates hematopoietic stem cell kinetics. Proc Natl Acad Sci U S A (1998) 1.22
Simian sarcoma-associated virus fails to infect Chinese hamster cells despite the presence of functional gibbon ape leukemia virus receptors. J Virol (1998) 1.21
Lymphocyte subset alterations and viral determinants of immunodeficiency disease induction by the feline leukemia virus FeLV-FAIDS. J Virol (1990) 1.18
Identification of envelope determinants of feline leukemia virus subgroup B that permit infection and gene transfer to cells expressing human Pit1 or Pit2. J Virol (2001) 1.18
Evolution of feline leukemia virus variant genomes with insertions, deletions, and defective envelope genes in infected cats with tumors. J Virol (1994) 1.16
Genetic determinants of feline leukemia virus-induced lymphoid tumors: patterns of proviral insertion and gene rearrangement. J Virol (1994) 1.07
Feline leukemia virus envelope sequences that affect T-cell tropism and syncytium formation are not part of known receptor-binding domains. J Virol (2000) 1.03
Isolation of a novel subgroup B feline leukemia virus from a cat infected with FeLV-A. Virology (1994) 1.01
Structure and pathogenicity of individual variants within an immunodeficiency disease-inducing isolate of FeLV. Virology (1992) 1.00
The host range and interference properties of two closely related feline leukemia variants suggest that they use distinct receptors. Virology (1998) 0.91
Colony forming T lymphocyte deficit in the development of feline retrovirus induced immunodeficiency syndrome. Blood (1989) 0.87
Analysis of FeLV-FAIDS provirus burden and productive infection in lymphocyte subsets in vivo. Virology (1996) 0.78
Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA (2000) 10.40
The origin of mutants. Nature (1988) 8.92
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med (1992) 4.90
Gender differences in HIV-1 diversity at time of infection. Nat Med (2000) 4.69
Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J Virol (1997) 4.19
Rapid method for screening dried blood samples on filter paper for human immunodeficiency virus type 1 DNA. J Clin Microbiol (1999) 3.88
Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol (2000) 3.83
Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat Med (1999) 3.11
Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis (2000) 3.02
Early drinking onset and its association with alcohol use and problem behavior in late adolescence. Prev Med (1996) 3.01
Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1. J Virol (1995) 2.98
Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Virol (1999) 2.90
Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet (1997) 2.88
The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis (2001) 2.79
A microwell cytotoxicity assay using Artemia salina (brine shrimp). Planta Med (1993) 2.69
Strong sequence conservation among horizontally transmissible, minimally pathogenic feline leukemia viruses. J Virol (1988) 2.62
Evolution of envelope sequences from the genital tract and peripheral blood of women infected with clade A human immunodeficiency virus type 1. J Virol (1998) 2.21
Why doctors don't use computers: some empirical findings. J R Soc Med (1986) 2.18
Characterization of a CD4-expressing macaque cell line that can detect virus after a single replication cycle and can be infected by diverse simian immunodeficiency virus isolates. Virology (1995) 2.08
Genital shedding of human immunodeficiency virus type 1 DNA during pregnancy: association with immunosuppression, abnormal cervical or vaginal discharge, and severe vitamin A deficiency. J Infect Dis (1997) 2.02
Results in 1,000 cases of therapeutic abortion managed by vacuum aspiration. Br Med J (1971) 2.02
Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest (2001) 2.01
Use of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 to assess the performance of viral RNA quantitation tests. J Clin Microbiol (2000) 1.95
Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS (2001) 1.88
Human immunodeficiency virus DNA in urethral secretions in men: association with gonococcal urethritis and CD4 cell depletion. J Infect Dis (1995) 1.86
Viral genetic determinants of T-cell killing and immunodeficiency disease induction by the feline leukemia virus FeLV-FAIDS. J Virol (1991) 1.83
Cell-free human immunodeficiency virus type 1 in breast milk. J Infect Dis (1998) 1.74
Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst (2001) 1.68
Cloning of the cellular receptor for feline leukemia virus subgroup C (FeLV-C), a retrovirus that induces red cell aplasia. Blood (2000) 1.64
Human immunodeficiency virus type 1-infected cells in breast milk: association with immunosuppression and vitamin A deficiency. J Infect Dis (1995) 1.62
Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties. J Virol (1999) 1.61
Vacuum aspiration of the uterus in therapeutic abortion. Br Med J (1970) 1.57
Molecular basis of human mitochondrial very-long-chain acyl-CoA dehydrogenase deficiency causing cardiomyopathy and sudden death in childhood. Proc Natl Acad Sci U S A (1995) 1.50
Identification of a cellular cofactor required for infection by feline leukemia virus. Science (2000) 1.49
Three distinct envelope domains, variably present in subgroup B feline leukemia virus recombinants, mediate Pit1 and Pit2 receptor recognition. J Virol (1997) 1.41
Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. J Virol (1999) 1.37
Progression to AIDS in macaques is associated with changes in the replication, tropism, and cytopathic properties of the simian immunodeficiency virus variant population. Virology (1995) 1.31
Transduction of Notch2 in feline leukemia virus-induced thymic lymphoma. J Virol (1996) 1.30
Phylogenetic evaluation of Kenyan HIV type 1 isolates. AIDS Res Hum Retroviruses (1997) 1.29
An investigation of genital ulcers in Jackson, Mississippi, with use of a multiplex polymerase chain reaction assay: high prevalence of chancroid and human immunodeficiency virus infection. J Infect Dis (1998) 1.26
In vivo evolution of a novel, syncytium-inducing and cytopathic feline leukemia virus variant. J Virol (1998) 1.23
Identification of envelope determinants of feline leukemia virus subgroup B that permit infection and gene transfer to cells expressing human Pit1 or Pit2. J Virol (2001) 1.18
Evolution of feline leukemia virus variant genomes with insertions, deletions, and defective envelope genes in infected cats with tumors. J Virol (1994) 1.16
Replication and persistence of simian immunodeficiency virus variants after passage in macaque lymphocytes and established human cell lines. J Virol (1993) 1.15
Physician utilization of computers in medical practice: policy implications based on a structural model. Soc Sci Med (1986) 1.13
Cervical and vaginal shedding of human immunodeficiency virus type 1-infected cells throughout the menstrual cycle. J Infect Dis (1998) 1.11
Evidence that an IRES within the Notch2 coding region can direct expression of a nuclear form of the protein. Mol Cell (2000) 1.10
The effects of plastocyanin on photophosphorylation. Biochim Biophys Acta (1969) 1.09
The effects of a blood-salvaging device on blood containing a hemoglobin-based oxygen carrier, HBOC-201. J Cardiothorac Vasc Anesth (1997) 1.07
The cytopathicity of a simian immunodeficiency virus Mne variant is determined by mutations in Gag and Env. J Virol (1997) 1.07
A prospective study of risk factors for herpes simplex virus type 2 acquisition among high-risk HIV-1 seronegative women in Kenya. Sex Transm Infect (2009) 1.06
Feline leukemia virus envelope sequences that affect T-cell tropism and syncytium formation are not part of known receptor-binding domains. J Virol (2000) 1.03
Effect of intrauterine device use on cervical shedding of HIV-1 DNA. AIDS (1999) 1.03
Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by human immunodeficiency virus type 1 subtype. J Virol (2009) 1.02
Cervical shedding of cytomegalovirus in human immunodeficiency virus type 1-infected women. J Med Virol (1999) 1.02
Design, methods, and conduct of the Optic Neuritis Treatment Trial. Control Clin Trials (1993) 1.01
Selenium deficiency is associated with shedding of HIV-1--infected cells in the female genital tract. J Acquir Immune Defic Syndr (2001) 1.01
Isolation of a novel subgroup B feline leukemia virus from a cat infected with FeLV-A. Virology (1994) 1.01
Persistence of simian immunodeficiency virus Mne variants upon transmission. J Virol (1994) 1.00
CCR5 promoter polymorphisms in a Kenyan perinatal human immunodeficiency virus type 1 cohort: association with increased 2-year maternal mortality. J Infect Dis (2001) 1.00
A lymph node-derived cytopathic simian immunodeficiency virus Mne variant replicates in nonstimulated peripheral blood mononuclear cells. J Virol (1998) 0.99
Informal communication networks and change in physicians' practice behavior. Res Med Educ (1988) 0.97
flvi-2, a target of retroviral insertional mutagenesis in feline thymic lymphosarcomas, encodes bmi-1. Oncogene (1993) 0.96
Role of Galactolipids in Spinach Chloroplast Lamellar Membranes: II. Effects of Galactolipid Depletion on Phosphorylation and Electron Flow. Plant Physiol (1976) 0.96
Rapid and sensitive assay for free fatty acids using rhodamine 6G. Anal Biochem (1972) 0.95
Coreceptor specificity of temporal variants of simian immunodeficiency virus Mne. J Virol (1999) 0.95
Feline Pit2 functions as a receptor for subgroup B feline leukemia viruses. J Virol (2001) 0.93
In vitro antiplasmodial, antiamoebic, and cytotoxic activities of some monomeric isoquinoline alkaloids. J Nat Prod (2000) 0.93
Maternal SDF1 3'A polymorphism is associated with increased perinatal human immunodeficiency virus type 1 transmission. J Virol (2000) 0.92
Plasmodium falciparum: effects of phaeanthine, a naturally-occurring bisbenzylisoquinoline alkaloid, on chloroquine-resistant and -sensitive parasites in vitro, and its influence on chloroquine activity. Ann Trop Med Parasitol (1991) 0.92
Refractive changes from use of silicone oil in vitreous surgery. Retina (1988) 0.91
The host range and interference properties of two closely related feline leukemia variants suggest that they use distinct receptors. Virology (1998) 0.91
Identification and deletion of sequences required for feline leukemia virus RNA packaging and construction of a high-titer feline leukemia virus packaging cell line. Virology (1996) 0.90
Transmission of the simian immunodeficiency virus SIVmne in macaques and baboons. J Med Primatol (1989) 0.90
In vivo selection of long terminal repeat alterations in feline leukemia virus-induced thymic lymphomas. Virology (1995) 0.89
Coincident involvement of flvi-2, c-myc, and novel env genes in natural and experimental lymphosarcomas induced by feline leukemia virus. Virology (1993) 0.88
In vitro antiplasmodial, antiamoebic, and cytotoxic activities of a series of bisbenzylisoquinoline alkaloids. Antimicrob Agents Chemother (1994) 0.87
Efficient isolation of human immunodeficiency virus type 1 RNA from cervical swabs. J Clin Microbiol (1998) 0.86
Implementation of the Abortion Act: report on a year's working of abortion clinics and operating sessions. Br Med J (1972) 0.86
NMR lipid profiles of cells, tissues, and body fluids: proton NMR analysis of human erythrocyte lipids. J Lipid Res (1994) 0.86
Infants with late breast milk acquisition of HIV-1 generate interferon-gamma responses more rapidly than infants with early peripartum acquisition. Clin Exp Immunol (2009) 0.85
Risk-taking behavior among Native American adolescents in Minnesota public schools: comparisons with black and white adolescents. Ethn Health (1996) 0.85
Hepatic microsomal metabolism and macromolecular binding of the antioxidant, N-phenyl-2-naphthylamine. Xenobiotica (1982) 0.85
FeLV-FAIDS-induced immunodeficiency syndrome in cats. Vet Immunol Immunopathol (1989) 0.84
In vitro NO and N2O inhibition of the branch point enzyme vitamin B12 dependent methionine synthase from rat brain synaptosomes. Biochem Soc Trans (1994) 0.84
Mutations within a putative cysteine loop of the transmembrane protein of an attenuated immunodeficiency-inducing feline leukemia virus variant inhibit envelope protein processing. J Virol (1995) 0.84
Intrarectal inoculation of macaques by the simian immunodeficiency virus, SIVmne E11S: CD4+ depletion and AIDS. J Med Primatol (1994) 0.84
Delayed cytopathicity of a feline leukemia virus variant is due to four mutations in the transmembrane protein gene. J Virol (1993) 0.82
Viral genetic variation, AIDS, and the multistep nature of carcinogenesis: the feline leukemia virus model. Leukemia (1996) 0.82
Overweight and obesity in native-American adolescents: comparing nonreservation youths with African-American and Caucasian peers. Am J Prev Med (1996) 0.81
Photodynamic inactivation of retrovirus by benzoporphyrin derivative: a feline leukemia virus model. Transfusion (1992) 0.80
Leukemic phase of mantle cell lymphoma, blastoid variant. Am J Clin Pathol (1999) 0.79
Regulation of the cellular thymidine kinase gene promoter in simian virus 40-infected cells. J Virol (1993) 0.79
Characterisation of drug resistant retroviral proteinase mutants. Biochem Soc Trans (1997) 0.79